For the evaluation of biochemical control of the disease, 74 (71.8%) patients reached biochemical control of acromegaly (IGF-1 ≤ ULN) with multimodal treatment during their follow-up, whereas 15 patients (14.6%) did not. The gene discussed is IGF1; the disease is acromegaly.